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1. Introduction 
Primary brain tumors have an annual incidence rate ranging between 7 and 19 new cases 
per 100,000 population. Metastatic tumors to the brain are more common, with more than 
100,000 patients per year in the United States. Gliomas are the most common primary brain 
tumors (DeAngelis, 2001). Among them, astrocytomas account for more than half of all 
primary malignancies of the central nervous system (CNS). They are classified into 4 grades: 
Grades I and II are considered as low-grade; anaplastic tumors (Grade III) and glioblastoma 
multiforme (Grade IV) are considered high-grade tumors. 
Glioblastoma multiforme (GBM) is the most common and most malignant of the glial 
tumors occurring in adults (Liu et al., 2010). Other types are oligodendrogliomas, 
ependymomas, meningiomas, pituitary adenomas, embryonal tumors and gangliogliomas. 
Among them meningiomas are the most common benign intracranial tumors, accounting for 
up to one fourth of all primary lesions (Whittle et al., 2004). The most common presenting 
symptoms of brain tumors are due to increased intracranial pressure (headache, nausea, 
vomiting), seizures, focal neurological deficits and possibly cognitive deterioration. 
With regards to treatment, in low-grade lesions radical surgical removal will generally allow 
functional survival for many years. Adjuvant radiotherapy can halt disease progress for a 
time and probably increases survival. For high-grade tumors surgical resection is almost 
always followed by radiotherapy and adjuvant chemotherapy that are usually given 
concomitantly. Temozolomide is the mainstay of treatment administered in parallel with 
and post-radiotherapy, with benefits in overall survival (Stupp et al., 2005). Patients younger 
than 60 years, with good functional status and gross total tumor resection have a better 
prognosis (Scott et al., 1999). 
Computed tomography (CT) and magnetic resonance imaging (MRI) are necessary to 
characterize gross tumor appearance, size and extension. Nevertheless, in patients with 
brain lesions it is not uncommon for radiomorphological modalities to provide non-specific 
information, even after infusion of iodine-based contrast media or gadolinium-based 
paramagnetic complexes. An enhancing lesion may represent a glioma, an abscess, a 
metastasis or even a primary CNS lymphoma. 
To gain additional diagnostic information from that acquired by conventional radiology, 
functional metabolic imaging by nuclear medicine techniques has been introduced, aiming 
to provide information related to the metabolic status of brain tumors. These metabolic 
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imaging modalities comprise single-photon emission computed tomography (SPECT) and 
positron emission tomography (PET). Although PET may be credited with providing the 
impetus for the new clinical interest in functional neuroimaging, SPECT has offered a 
credible alternative with the advantage of lower cost and wider availability. 
Various single-photon emitting radiotracers have been used to date, thallium-201 (201Tl) 
being among the first and mostly studied. Technetium-99m (99mTc)-labeled compounds have 
also been evaluated, including 99mTc-methionine, 99mTc-glucoheptonate and more 
extensively 99mTc-hexakis-2-methoxy isobutyl isonitrile (99mTc-sestamibi or 99mTc-MIBI). For 
a number of reasons including higher photon flux, better spatial resolution, less radiation 
burden to the patient and excellent availability, the use of 99mTc-based compounds has 
progressively prevailed over 201Tl. 
 99mTc-tetrofosmin (99mTc-TF) is another 99mTc-based SPECT radiotracer that demonstrates 
certain similarities with 99mTc-MIBI. Both are routinely used for myocardial perfusion 
imaging, but also exhibit tumor-seeking properties. Whereas 99mTc-MIBI has been 
extensively evaluated in imaging brain tumors for nearly two decades, 99mTc-TF has been 
introduced in this field for a considerably shorter period of time. 
2. The radiotracer and its cellular uptake mechanism 
99mTc-TF is a lipophilic cationic diphosphine routinely used for myocardial perfusion 
imaging and has also been shown to exhibit certain tumor-seeking properties. These 
properties have been verified in various neoplasms including parathyroid adenoma and 
several carcinomas (e.g. of the breast, thyroid, nasopharynx and lung). Its uptake by 
intracranial tumors is under meticulous investigation during the past few years. 
After intravenous administration, the tracer reaches the brain by the arterial blood flow. 
Despite being a lipophilic molecule, 99mTc-TF cannot cross the intact blood-brain barrier 
(BBB), which results in negligible tracer uptake in the healthy brain parenchyma. There is, 
however, some tracer accumulation normally occurring in the choroid plexuses and the 
pituitary gland, brain structures that lack BBB. 
In order for 99mTc-TF to be taken up by the cells of a brain lesion, this has to disrupt the BBB. 
Its uptake mechanism depends on the blood flow to the lesion, as well as on the integrity of 
the membrane of the lesion cells, an indicator of their viability. The tracer enters viable cells 
mainly via passive transport, driven by the negative electric potential of the intact cell 
membrane, and it mostly localizes within the cytosol, with only a fraction passing into the 
mitochondria. In that sense, cellular 99mTc-TF uptake mainly reflects on the viability of lesion 
cells and their metabolic status. 
As discussed in the following paragraphs, initial clinical evidence from in vivo studies 
suggests that there is a significant correlation between tracer uptake and cellular 
proliferation in both gliomas and meningiomas (Alexiou et al., 2008a, 2008b; Fotopoulos et 
al., 2008). Cellular proliferative activity may thus be regarded as a major driving force that 
leads to significant intracellular tracer accumulation and retention. 
Other studies on human glioma cell lines in vitro and in vivo revealed that 99mTc-TF is 
influenced to a very small degree by the expression of P-glycoprotein (P-gp) (Le Jeune et al., 
2005; Alexiou et al., 2011). P-gp is a membrane protein encoded by the multi-drug resistance 
(MDR) gene and acts as an ATP-dependent drug efflux pump, excreting anticancer 
pharmaceuticals and radiopharmaceutical imaging agents outside the tumor cell. Although 
both 99mTc-TF and 99mTc-MIBI have been found in vitro to be substrates of P-gp, the fact that 
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99mTc-TF uptake in glioma cells is not particularly influenced by the expression of their MDR 
protein genotype substantiates a plausible clinical superiority over 99mTc-MIBI, which is 
prone to extracellular excretion by P-gp. 
3. Protocol of brain SPECT imaging 
The radiopharmaceutical is prepared in the nuclear medicine department with the use of a 
commercially available powder kit (Myoview™, General Electric Healthcare Ltd., 
Buckinghamshire, UK), which is reconstituted with freshly eluted 99mTc pertechnetate 
(99mTcO4-) sterile solution. Comparison of 99mTc-TF uptake in various types of lesions during 
imaging performed consecutively at 20, 40 and 120 min post-injection did not reveal any 
considerable fluctuations of relative tracer uptake over time (Soricelli et al., 1998). Hence, 
image acquisition at 20–30 min after radiotracer administration can be safely adopted as a 
convenient rule of thumb. The radiopharmaceutical is injected intravenously, at an 
administered activity of approximately 740-925 MBq (20-25 mCi). 
All SPECT studies in our department are implemented on the same dual-head γ-camera 
(Millennium™ VG3, General Electric Medical Systems – Europe, Buc Cedex, France), 
equipped with a pair of low-energy, high-resolution, parallel-hole collimators. The matrix is 
set at 128  128 pixels; the photopeak is centered at 140 keV, allowing a symmetrical 10% 
window. The tomographic imaging parameters consist of a full-circle (360°) rotation angle, a 
3°-step-and-shoot technique and an acquisition time of 30 sec per frame. Raw imaging data 
are reconstructed using the Butterworth-filtered back-projection algorithm (critical 
frequency [order]: 0.25; filter power: 5.0), generating tomographic views of the brain in the 
three planes (transverse, coronal and sagittal). In the case of γ-cameras with an integrated 
computed tomograph (hybrid SPECT/CT systems), data from a low-dose CT scan can be 
used for attenuation correction of the scintigraphic image. In non-hybrid modalities —
currently comprising the vast majority— attenuation correction can be applied empirically 
during tomographic image reconstruction following the Chang method (attenuation factor: 
0.11/cm). 
3.1 Image analysis and interpretation 
Radiotracer uptake in the brain is first assessed visually. 99mTc-TF cannot penetrate the intact 
BBB and does not accumulate in the normal brain parenchyma, so any abnormal uptake is 
readily identifiable against the negligible normal-brain background. Exceptions to this are 
the choroid plexuses and the pituitary, structures that lack BBB so they normally accumulate 
an amount of the tracer (Fig. 1). Space-occupying lesions adjacent to these structures could 
face obvious limitations in delineating their true scintigraphic margins and estimate the 
tracer uptake that is attributable to the lesion per se. 
Semi-automated, semi-quantitative image analysis is a valuable adjunct to the objective 
visual image reading and adds subjectivity to the interpretation of the study. It is applied on 
the reconstructed SPECT images by calculating the lesion-to-normal (L/N) ratio of relative 
radiotracer uptake —hence the term ‘semi-quantitative’. In our department the transversal 
SPECT slice in which lesion tracer uptake appears to be maximal is chosen manually — 
hence the term ‘semi-automated’. This is performed in close reference to the corresponding 
CT/MRI transversal slices that serve as a reference guide of the lesion’s topography. 
After the selection of the slice with maximal lesion uptake, relative tracer concentration is 
calculated with the use of the Java-based, open-source image processing software ImageJ 
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(http://rsb.info.nih.gov/ij/index.html), developed by the National Institutes of Health. A 
region of interest (ROI) encircling the lesion is defined manually on the selected transversal 
slice and a second identical (mirror) region is drawn on the contra lateral normal side of the 
brain (Fig. 2). The L/N ratio is calculated by dividing the average counts in the lesion ROI 
by those in the contra lateral (background) ROI. The ROIs are independently evaluated for 
eligibility by two experienced nuclear medicine physicians and possible disagreements are 
resolved by consensus. 
 
 
Fig. 1. A normal 99mTc-tetrofosmin brain SPECT study (transversal slicing in three different 
planes) displaying physiological tracer accumulation in the choroid plexuses (arrow), the 
pituitary (arrowhead) and the scalp. 
 
 
Fig. 2. ROI definition over the lesion (L) and over the normal brain parenchyma (N). 
The application of the above methodology for L/N ratio calculation in everyday clinical 
practice is, in most cases, a straightforward process that provides reproducible results 
without significant deviations. Nevertheless, the location of the lesion within the brain and 
its morphology are critical factors for the application and effectiveness of the proposed 
technique. Lesion adjacency to anatomical structures with normal tracer uptake (choroid 
plexus, pituitary) increases the difficulty of reliable L/N calculation and the chances of its 
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overestimation. In such cases, the operator has to make sure that the lesion ROI avoids 
normal structure uptake and encompasses only areas unquestionably pathologic, even if 
these do not appear to exhibit the maximum intensity of relative tracer uptake. 
Heterogeneity of tracer distribution within a lesion (e.g. due to local necrosis) may impose 
L/N calculation in more than one areas/SPECT slices. When large variations in tracer 
uptake intensity are apparent, a tight ROI around the highest uptake region may be more 
reliable than a looser one, which could lead to L/N underestimation. For lesions located 
around the midline there may not be a definite mirror area to draw the normal ROI; a 
nearby site could be safely selected in the majority of similar cases, since the level of the 
background activity is generally very low throughout. 
4. Clinical applications 
Our experience thus far with 99mTc-TF is based on its clinical use in SPECT imaging studies 
performed in nearly 200 cases of space-occupying brain lesions. Obtained results to date 
conform to the fact that 99mTc-TF brain SPECT can contribute substantial functional 
information to the structural data already obtained by CT and conventional MRI, thus 
helping to establish non-invasively an accurate diagnosis. Furthermore, based on 
observations in patients with high-grade gliomas, it looks like this radiotracer also carries a 
plausible prognostic role that merits further investigation. 
In the following paragraphs the discussion will focus on the experience gained so far by the 
use of 99mTc-TF SPECT in the management of patients treated for brain tumor; the role of 
other SPECT and PET radiotracers and of other CNS imaging modalities such as 
conventional and functional MRI will also be mentioned. 
4.1 Evaluation of intracranial space-occupying lesions: differentiation of high-grade 
from low-grade gliomas and non-neoplastic pathologies 
Differentiating neoplastic from non-neoplastic intra-axial lesions is of paramount 
importance for patient management. Neoplastic and non-neoplastic pathologies may 
equally produce abnormal contrast enhancement, mass effects and perilesional edema on 
CT and classic MRI (Al-Okaili et al., 2007). Consequently, such clinical situations often 
constitute a diagnostic dilemma and it is not uncommon to seek the help of histological 
verification to establish a diagnosis. 
The data of a prospectively implemented study comprising 106 patients hospitalized in the 
neurosurgery department of our institution over a 5-year period (between September 2004 
and September 2009) were analyzed recently; all cases have been submitted to surgery due 
to an intracranial lesion suspicious of tumor on conventional radiological imaging. The 
patients underwent 99mTc-TF brain SPECT within a 7-10 day period after radiological 
diagnosis, with surgery following shortly after SPECT to establish histologically the final 
diagnosis. The only cases that did not receive surgery were among previously treated 
tumors resubmitted owning to suspected recurrence. These individuals were closely 
followed-up clinically and radiologically over a period of 6 months, to verify stability 
suggestive of radionecrosis, or on the other hand, disease progression consistent with tumor 
relapse. 
Ninety patients suffered from neoplastic lesions and 16 harbored non-neoplastic pathologies 
(abscesses, non-malignant hemorrhages, radiation necroses). 99mTc-TF was taken up more 
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avidly by high-grade gliomas (Fig. 3) than by low-grade lesions and could reliably 
distinguish them, with an L/N ratio of 2.8 providing the optimal discrimination threshold 
(Fotopoulos et al., 2011). Similar findings have also been reported by other authors (Choi et 
al., 2000). Furthermore, 99mTc-TF differentiated effectively high- and low-grade gliomas from 
non-neoplastic lesions. Nonetheless, differentiation between gliomas between gliomas —
either low- or high-grade— and metastases was not feasible on the basis of scintigraphic 
(L/N) criteria. 
 
 
Fig. 3. High-grade glioma associated with significant tracer uptake (L/N=16). 
Several other SPECT tracers have been used for the initial evaluation of brain lesions. 201Tl 
was able to differentiate malignant tumors from poorly vascularized benign lesions, yet 
faced a limited ability to separate between the latter and low-grade astrocytomas, as well as 
tumors from abscesses (Staffen et al., 1998; Kinuya et al., 2002). 99mTc-MIBI has been 
evaluated in various brain pathologies. If performed within 5 days of symptom onset, it has 
been found capable of differentiating neoplastic from non-neoplastic intracerebral 
hematomas (Minutoli et al., 2005). Iodine-123-α-methyl tyrosine (123I-IMT) was also among 
the SPECT tracers to provide encouraging results for imaging tumor recurrence (Samnick et 
al., 2002). 
4.1.1 Discriminating recurrent disease from radiation necrosis in previously treated 
tumors 
Treatment of brain gliomas depends on their localisation, cell type and grade of malignancy. 
It normally combines surgery, radiation therapy and chemotherapy. Radiotherapy —in the 
form of external beam radiation, brachytherapy, or stereotactic radiotherapy— consists the 
primary adjuvant treatment after surgical resection. Among the delayed side effects of 
radiation therapy, radionecrosis is the most prominent, primarily depending on the 
administered dose and rate of delivery and usually occurs within 6 months to 2 years, the 
same period during which disease recurrence is also rather frequent (Marks & Wong, 1985). 
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Radiation injury is usually localized around the tumor bed umor bed —where recurrent 
glioma is also typically located—, although occasional reports describe necrosis arising 
anywhere in the path of the irradiation beam. It is not uncommon for radiation injury and 
recurrent disease to coexist. 
Since these two entities have diverse treatment approach and prognosis, differentiation 
between them is crucial and several imaging techniques have been evaluated towards this 
objective. Morphological depiction of the brain by classic MRI and CT can merely recognize 
edema and BBB disruption, so it is usually inconclusive and faces inherent limitations in 
discriminating viable tumor from post-irradiation change (Byrne, 1994). 
Depiction of recurrent tumor was the first imaging challenge against which we evaluated 
99mTc-TF brain SPECT accuracy a few years back (Alexiou et al., 2007). A prospective 
ongoing study enrolled 24 patients that had been previously treated surgically for brain 
tumor followed by external beam radiotherapy, while some had also received adjuvant 
chemotherapy. No residual tumor had been recognized on radiological imaging 
immediately after initial treatment. On follow-up they developed neurological 
symptomatology consistent with tumor recurrence, with radiological investigation verifying 
the presence of a contrast-enhancing lesion with edema and mass effects. In 5 cases surgical 
excision of the lesion was performed within a week after 99mTc-TF scintigraphy and a 
diagnosis was reached histologically. In the rest the diagnosis was based on clinical and 
neuromorphological follow-up, owning to various reasons (technically inoperable lesions, 
critical clinical condition, patient refusal to re-operate etc.). A 6-month ‘wait-and-see’ period 
is considered sufficient by most to reach a safe estimation of the diagnosis. This is because 
by that time glioma growth within the limited space of the cranial cavity will definitelly 
result in clinical deterioration and radiological progression, which may safely be considered 
as indicative of recurrence. 
On tumor recurrence SPECT depicted increased 99mTc-TF uptake in the region of the brain 
that corresponded to the radiologically detected lesion, suggesting the presence of viable 
hypermetabolic tissue (Fig. 4). On the contrary, radionecrotic lesions tended to exhibit 
significantly fainter tracer uptake (Fig. 5). Receiver operating characteristic (ROC) curve 
statistical analysis returned a threshold L/N value of 4.8 as most accurately discriminating 
these two clinical entities. However, it must be kept in mind that, according to relevant 
reports, 99mTc-TF SPECT exhibits suboptimal sensitivity in detecting recurrence of tumors 
located subtentorially in the posterior fossa (Barai et al., 2003). 
 201Tl was one of the first single-photon emitting radiotracers evaluated in the same 
clinical setting. Published data thus far suggest a wide range of sensitivity and specificity 
in detecting tumor recurrence in patients with previously treated supratentorial gliomas, 
partially owning to varying occurrence of false positives; still 201Tl SPECT is reported to 
have an advantage over conventional MRI (Vos et al., 2007). 99mTc-MIBI has also been 
extensively evaluated with good reported results and a significant diagnostic advantage 
over contrast-enhanced MRI (Soler et al., 1998). Imaging protein synthesis using 
radiolabeled amino acids is another approach employed towards non-invasive revelation 
of tumor recurrence. Various natural amino acids have been labeled with radioactive 
isotopes —mostly PET— and are currently investigated. As regards SPECT, encouraging 
results were reported for 99mTc-methionine and 123I-IMT (Barai et al., 2004; Samnick et al., 
2002). 
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Fig. 4. Recurrent astrocytoma characterized by intense tracer uptake (L/N=8.7). 
 
Fig. 5. Radiation necrosis exhibiting only mildly increased tracer uptake (L/N=2.9). 
4.1.2 Spontaneous intracerebral hemorrhage: Masking an underlying neoplasm? 
With reference to non-traumatic intracerebral hemorrhage (ICH), distinguishing a neoplastic 
from a non-neoplastic one constitutes a challenging task, since neoplasms can be hidden 
behind an intracerebral hematoma, while some non-neoplastic hemorrhages may mimic 
neoplasms on standard radiomorphological imaging. Bleeding deriving from a malignant 
brain lesion accounts for approximately 10% of all ICHs, with metastases displaying the 
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highest susceptibility. The pre-operative diagnosis of a tumor as the underlying cause of an 
ICH is usually very difficult for CT and MRI, even for the modern functional MRI 
techniques. Hence diagnosis is based on evolution patterns of the hematoma in a series of 
sequential radiological studies over a period of several weeks, until the extravasated blood 
is absorbed so the tumor revealed. 
 99mTc-TF SPECT can play a role in differentiating neoplastic from non-neoplastic 
hemorrhages, since only the latter exhibit negligible to no radiotracer uptake (Alexiou et al., 
2006) (Fig. 6). Our experience is based on an increasing series of patients with spontaneous 
ICH referred to our department, most of whom bear some kind of malignancy. Out of the 8 
cases reviewed so far, in half the diagnosis was based on surgery and on a ‘wait-and-see’ 
clinical and morphologic follow-up in the rest. Although only two hemorrhages were finally 
proven to be of neoplastic origin, 99mTc-TF SPECT managed to accurately identify both 
(Fotopoulos et al., 2011). 
 
 
Fig. 6. Intracerebral hemorrhage without signs of tracer uptake, suggesting a benign origin 
(A, B). On the other hand, a cerebellar hemorrhage exhibits significant tracer uptake (arrow), 
strongly suggesting the presence of an underlying neoplasm (C, D). 
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4.2 Assessment of glioma aggressiveness 
Assessing the proliferative potential of tumor cells is of paramount importance for 
predicting their biological behavior, response to therapy and prognosis. Proliferation is 
equally important in gliomas, since patients with the same histopathological profile that 
receive equivalent treatment may display diverse natural history and prognosis, owning to 
differences in the proliferative potential of their disease. 
As a result, various methodologies and immunohistological markers have been developed 
to estimate proliferation in tissue samples. MIB-1 antibody immunostaining to the nuclear 
antigen Ki-67 is performed routinely and is considered as the most reliable proliferation 
index, since it is expressed in nearly all phases of the cell cycle, with the exception of phase 
G0  (McKeever et al., 1997). Flow cytometry assessing DNA ploidy and S-phase fraction can 
also provide reliable clues on glioma aggressiveness (Garcia et al., 1997). Nevertheless, these 
methods require tissue sampling through biopsy or over the course of a surgical procedure. 
It is therefore equally important for functional imaging to develop radiolabeled tracers that 
can provide non-invasively an accurate in vivo estimate of glioma proliferation. 
In a prospective pilot study we evaluated the relationship between glioma proliferation, as 
expressed by the Ki-67 immunohistological index, and 99mTc-TF uptake. Patients bearing 
space-occupying lesions suspicious of glioma on structural brain imaging were enrolled. 
Within a week after SPECT imaging the lesion was removed surgically and Ki-67 was 
assessed in the excised specimens. The diagnosed tumors were glioblastoma multiforme (6 
cases), anaplastic astrocytoma (1), anaplastic oligodendroglioma (2), low-grade 
oligodendroglioma (1), and low-grade astrocytoma (1). Statistical analysis revealed a strong 
positive linear correlation between L/N tracer uptake ratio and Ki-67 expression (Alexiou et 
al., 2008a). These initial results were supported by another prospective study to follow, in 
which we sought for a possible correlation between 99mTc-TF uptake and glioma 
proliferative activity assessed by flow cytometry. Again, a significant positive linear 
correlation between radiotracer uptake and the fraction of tumor cells on the S-phase of the 
cell cycle was verified (Alexiou et al., 2008b). 
As regards other SPECT radiotracers, 201Tl was one of the first studied. Reports described a 
correlation with bromodeoxyuridine (BrdU) and proliferating cell nuclear antigen (PCNA) 
tissue labeling indices (Oriuchi et al., 1993; Ishibashi et al., 1995; Gungor et al., 2000). 99mTc-
MIBI was found to display a positive correlation with glioma proliferation, as assessed by 
both flow cytometry and Ki-67, and this was stronger compared to 201Tl (Ak et al., 2003; 
Nagamachi et al., 2001). With regards to labeled amino acid SPECT, 123I-IMT was similarly 
reported to correlate with Ki-67 expression (Kuwert et al., 1997). Finally, pentavalent 99mTc-
dimercapto-succinic acid (99mTc-[V]DMSA) is another tumor-seeking tracer whose 
proliferative imaging potential in gliomas has been suggested in vitro and sporadically 
reported in vivo (Denoyer et al., 2005; Tsiouris et al., 2007). 
4.3 Assessment of meningiomas: differentiation between typical and anaplastic and 
estimation of aggressiveness 
Meningiomas account for nearly 30% of all intracranial tumors and are usually diagnosed 
after the third decade of life, being twice more frequent in women. According to the World 
Health Organization (WHO) they are classified into benign (grade I), atypical (grade II) and 
anaplastic/malignant (grade III) (Lamszus, 2004). Although they usually have a relatively 
benign clinical course and only a 15% recurrence rate, atypical and malignant lesions are 
associated with high recurrence rates and poor outcome (Kayaselcuk et al., 2004). Their 
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proliferative potential is essential for their biological characterization, which affects patient 
management and has prognostic implications. Hence, similarly to gliomas, their non-
invasive metabolic characterization constitutes a major objective for CNS imaging. 
As with gliomas, we investigated prospectively whether 99mTc-TF SPECT can provide useful 
clues for meningioma grade and cellular proliferative activity. After radiomorphological 
imaging revealed the lesion, scintigraphic imaging by 99mTc-TF was performed within a 
week before surgical excision and the surgical specimens were graded following the WHO 
criteria and stained for Ki-67. The intensity of tumoral radiotracer uptake ranged from 
restrained to prominent. Malignant lesions tended to exhibit a significantly higher uptake 
compared to lesions of low histological grade. ROC analysis provided an L/N ratio value of 
9.6 as the optimal cut-off point thresholding the two groups. L/N tracer uptake analysis also 
revealed a significant linear correlation with both meningioma grade and Ki-67 expression 
(Fotopoulos et al., 2008). These findings pertaining to Ki-67 were sustained by another 
study, which aimed to correlate meningioma tracer uptake with its proliferative profile, as 
assessed by flow cytometry. Result analysis revealed a significant correlation of 99mTc-TF 
uptake with both the S-phase fraction and the level of DNA aneuploidy (Alexiou et al., 
2008b). 
 201Tl was among the first single-photon emitting radiotracers studied in meningioma. Its 
uptake pre-operatively has been proposed to differentiate meningiomas with different 
biological behaviors, while tracer retention by a lesion correlated with its malignant 
potential (Jinnouchi et al., 1993; Tedeschi et al., 1996). Nevertheless, later reports did not 
verify any correlation between 201Tl uptake and PCNA labeling index in meningiomas, 
dissimilar to gliomas (Gungor et al., 2000). 
4.4 Patient prognosis 
Glioblastoma is the most common and most malignant of the glial tumors occurring in 
adults, with unfavorable prognosis. Even so, a subset of patients demonstrates long-term 
survival reaching or even exceeding three years. Since no reliable biomarker has been 
established for use in clinical practice, prognostic factors already proposed are age at 
diagnosis, the Karnofsky Performance Score (KPS) and extent of surgical resection, although 
these inadequately predict outcome (Scott et al., 1999; Lacroix et al., 2001). Identification of 
solid prognostic variables could recognize patients that may benefit from aggressive 
treatment schemes and allow for the selection of more homogenous populations in clinical 
trials. 
The correlation between in vivo 99mTc-TF uptake and glioma proliferation, as assessed by the 
Ki-67 index and flow cytometry, has already been described (Alexiou et al., 2008a, 2008b). 
Due to the established prognostic value of Ki-67 in gliomas, investigating a possible 
association between pre-treatment tumoral tracer uptake and overall survival seemed as the 
next logical step. We followed-up 18 newly diagnosed GBM cases who had been submitted 
to 99mTc-TF SPECT prior to surgery. All patients received post-operative standard 
radiotherapy (6000 rads) with adjuvant temozolomide chemotherapy and then 
temozolomide up to a year after surgery, or until recurrence. Cases of tumor recurrence 
were treated by supportive care, with no additional surgery or chemotherapy. Patients 
bearing lesions with radiotracer L/N uptake 4.7 or less exhibited significantly better 
survival compared to those with a ratio exceeding 4.7. KPS exceeding 90 was also associated 
with a better course. Patients with near-total resection or aged under 60 displayed a longer 
survival trend, although not statistically significant. Multivariate analysis similarly proved 
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radiotracer uptake and KPS as the only variables with independent prognostic power 
(Alexiou et al., 2010). 
The prognostic value of tumoral 201Tl uptake has been evaluated in the same clinical context 
and was found associated with worse survival for lesions located supratentorially (Oriuchi 
et al., 1993). Post-treatment 99mTc-MIBI uptake has also been described to exhibit prognostic 
implications in high-grade gliomas and similar results were also reported for 123I-IMT 
(Beauchesne et al., 2004; Weber et al., 2001). 
5. Other metabolic imaging modalities: PET 
Brain PET imaging is extensively evaluated towards the distinction between tumors and 
non-neoplastic brain lesions. Although initial results for fluorine-18 fluoro-deoxyglucose 
(18F-FDG) PET were encouraging, later studies revealed considerable limitations and, for 
that reason, other positron-emitting radiotracers were put under perspective (Ricci et al., 
1998). Carbon-11 methionine (¹¹C-MET) gave promising results, yet it suffers limited 
availability owning to the need of an on-site cyclotron to produce the short-lived 11C 
(Galldiks et al., 2010). 18F-fluoro-choline, O-(2-[18F]fluoro-ethyl)-L-tyrosine (18F-FET) and 3,4-
dihydroxy-6-18F-fluoro-L-phenylalanine (18F-FDOPA) are PET tracers that have been proven 
superior to 18F-FDG for brain tumor imaging (Kwee et al., 2007; Pauleit et al., 2009; Chen et 
al., 2006). 
Diagnosis of brain tumor recurrence has been an imaging challenge also for PET. Although 
initial reports for 18F-FDG were encouraging (Di Chiro et al., 1988), more recent studies 
questioned its diagnostic accuracy, which was found considerably inferior to that of 201Tl 
SPECT in several series (Kahn et al., 1994; Gómez-Río et al., 2008). A significant 
disadvantage of 18F-FDG derives from its physiological uptake in the glucose-metabolizing 
normal brain. For that reason other tumor-seeking positron-emitting radiotracers have been 
developed. 11C-MET PET has given superior results compared to 18F-FDG because of its 
sensitivity and clearer delineation of recurrence (Van Laere et al., 2005), yet suffers limited 
availability due to the need of an on-site cyclotron to produce 11C and the same applies for 
13N-NH3 (ammonia), which has also been tried (Xiangsong et al., 2006). Perhaps the most 
promising PET tracers to date are the labeled analogues of thymidine, 3'-deoxy-3'-18F-fluoro-
thymidine (18F-FLT) and of tyrosine, 18F-FET. Their greatest advantage compared to other 
PET tracers lies in their low uptake by normal brain parenchyma, thus providing a better 
contrast between tumor and normal brain. Initial experience gained from a series of studies 
suggests that these agents are superior to 18F-FDG and to conventional MRI in 
distinguishing tumor recurrence from radiation-induced brain injury (Chen et al., 2005; 
Pöpperl et al., 2004). 
PET has been widely utilized to evaluate glioma proliferation. The uptake kinetics of 18F-
FDG reflect glucose metabolism, whose modifications are only indirectly related to the 
proliferation status of the tumor. Moreover, the physiological high dependence of normal 
brain on glucose metabolism results in normally increased fluoro-deoxyglucose uptake, 
which accounts for the tracer’s suboptimal diagnostic performance. Among radiolabeled 
amino acids, 11C-MET is the most extensively studied with encouraging results, still the 
short-lived 11C precludes its use in centers without a cyclotron on-site (Kim et al., 2005; 
Hatakeyama et al., 2008). 11C-thymidine PET is of great interest, since thymidine is the 
native pyrimidine base used in DNA synthesis, yet suffers from rapid in vivo degradation 
and the limited availability issues of 11C. To overcome these restrictions, 18F-FLT has been 
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developed as an alternative estimator of the DNA synthesis rate and is currently proving a 
useful proliferation imaging tracer, correlating well with Ki-67 (Shields et al., 1996; Ullrich et 
al., 2008). 
As in CNS gliomas, 18F-FDG uptake kinetics in meningiomas reflect on glucose metabolism 
that is only indirectly related to proliferation. In a pilot PET study comprising 11C-MET, 
tracer uptake succesfully predicted meningioma proliferation (Ki-67) (Iuchi et al., 1999). 18F-
FLT also holds plenty of theoretical advantages that remain to be proven in practice. 
6. Functional MRI techniques 
Conventional radiomorphological imaging —in the form of CT and classic MRI— may face 
significant limitations in discriminating benign from malignant intracranial space-occupying 
pathologies, since these modalities basically recognize BBB disruption, mass-effects and 
edema that can equally accompany both categories of lesions. An answer to these limitations 
towards the discrimination of neoplastic from non-neoplastic lesions has been attempted by 
the introduction of functional MRI techniques, namely perfusion MRI and MR spectroscopy 
(MRS). 
Perfusion MRI estimates tumor neovascularity and capillary permeability in vivo, by 
measuring the relative cerebral blood volume (rCBV); higher vascularity usually 
corresponds to a more aggressive pathology. In the diagnosis between tumor recurrence and 
radiation injury, perfusion MR holds a role by measuring vascularity within the suspicious 
brain areas. Since vasculature adjusts perfusion to meet metabolic tissue demands, rich 
vascularity can be an indirect measure of increased tissue metabolism, with relapsing tumor 
generally being highly vascular as opposed to radionecrosis (Covarrubias et al., 2004). 
Proton MRS is able to depict the metabolic composition of a tissue, by detecting the relative 
concentrations of several major metabolites such as choline (Cho), creatine (Cr), N-acetyl 
aspartate (NAA) and other macromolecules. NAA is predominantly localized in neurons, 
Cho is a marker of cell membrane metabolism and Cr reflects energy metabolism. Despite 
no tumor-specific metabolite has been identified to date, an increased level of Cho with 
decreased NAA and Cr were proven suggestive of brain tumor (Hollingworth et al., 2006). 
MRS has been evaluated by several investigators for the differentiation of neoplastic from 
non-neoplastic intra-axial lesions — such as brain abscess, demyelination, infarct and 
radiation necrosis —  with good results. The Cho/Cr and Cho/NAA ratios tend to increase 
in cases of tumor reccurence and thus contribute to its differentiation from radiation injury 
(Ando et al., 2004). This modality has also been evaluated for the non-invasive assessment of 
glioma aggressiveness, with initial findings associating Cho/Cr and Cho/NAA ratios with 
proliferative activity (Shimizu et al., 2000; Tamiya et al., 2000). 
Diffusion weighted imaging (DWI) and diffusion tensor imaging (DTI) constitute modern 
functional MR techniques, which reflect on the viability and structure of tissues at the 
cellular level. Their role in differentiating between tumor recurrence and radionecrosis is 
under study (Hein et al., 2004; Sundgren et al., 2006), while it also remains to be determined 
whether they can provide findings clearly linkable to glioma proliferative activity. 
7. Advantages of 99mTc-TF for brain SPECT imaging 
The 99mTc-labeled compounds 99mTc-TF and 99mTc-MIBI bear certain imaging characteristics 
that are proven advantageous over 201Tl. The single-photon (γ-ray) emitted by 99mTc peaks at 
www.intechopen.com
 Diagnostic Techniques and Surgical Management of Brain Tumors 
 
316 
140 keV, which is optimal for imaging in the γ-camera, while its higher photon flux results 
in improved spatial resolution and less radiation burden to the patient. Of note is the 
excellent availability of 99mTc in every nuclear medicine department. 
 99mTc-TF shares a similar cellular uptake mechanism with 99mTc-MIBI, yet it mostly localizes 
within the cytosol, whereas the latter accumulates predominantly in the mitochondria. In 
vitro studies in glioma cell lines substantiated a plausible clinical superiority of 99mTc-TF 
over 99mTc-MIBI in imaging gliomas and meningiomas, largely due to the considerably 
lesser reliance of its intracellular concentration on cellular MDR expression (P-gp) (Le Jeune 
et al., 2005). In a recent study we verified in vivo this non-dependence of 99mTc-TF uptake on 
the glioma MDR phenotype, suggesting that it constitutes an appropriate radiotracer for 
glioma imaging, although less ideal for identifying P-gp-avid lesions that are likely to 
respond poorly to chemotherapy (Alexiou et al., 2011). 
8. Limitations of 99mTc-TF brain SPECT 
The method’s limitations derive mainly from the nature of 99mTc-TF kinetics in the brain. 
Although it does not cross the intact BBB, which drastically results in its negligible 
concentration in the normal brain parenchyma, it physiologically accumulates in the choroid 
plexuses and the pituitary gland, which are structures normally lacking BBB. Physiological 
tracer activity comes also from the scalp. This normal uptake may therefore hamper image 
processing by hindering precise ROI definition for lesions lying adjacently to these 
anatomical structures and this can prove elaborate even under CT/MRI guidance. In such 
cases, hybrid SPECT/CT modalities could partially overcome this limitation by providing 
better spatial tumor localization to co-register with SPECT and also by applying attenuation 
correction to SPECT image processing and L/N calculation. 
Apart from the proximity to areas of normal tracer uptake, location also matters when it 
comes to lesions sited subtentorially. There are reports suggesting that tumors of the 
posterior fossa tend to exhibit a lower-than-anticipated tracer uptake that hinders diagnostic 
accuracy (Barai et al., 2003). 
Inherent to the integrity of the BBB is also the fact that 99mTc-TF has limited ability to 
penetrate into and characterize metabolically those brain lesions that do not exhibit contrast-
enhancement on radiological imaging. Non-enhancement is an indicator of a non-ruptured 
BBB and is usually observed in low-grade gliomas. 
Limitations innate to SPECT instrumentation ought not to be ignored. Spatial resolution is 
confined to 7.0 mm on ideal situations. In practice this limit usually reaches larger values 
(8.0-1.0 cm) due to various reasons, which can significantly affect the modality’s ability to 
depict small lesions sized close to that limit. 
We should not disregard certain restrictions originating from study design and 
implementation. Our experience thus far derives from small-scale studies implemented on a 
single-institution basis and with relatively small numbers of cases. Possible limitations 
might also emerge from the lack of histological verification in subgroups of the enrolled 
patients, like in those studies aiming to distinguish tumor recurrence from radionecrosis. 
Although histology provides the definitive diagnosis, this cannot always be achieved, as in 
cases of patient denying surgery or when surgical access to the lesion is not feasible. In such 
instances, a 6-month clinical and radiomorphological close follow-up could provide an 
acceptable diagnostic alternative, as explained earlier. 
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9. Conclusion 
Radiomorphological imaging of the brain by conventional MRI and CT is of paramount 
importance in identifying structural abnormalities secondary to the development of space-
occupying lesions, especially when those pathologies disrupt the BBB and give rise to 
contrast enhancement, edema and mass effects. Nevertheless, the true nature of each visible 
lesion may lie well beyond gross structural patterns, down to the cellular and molecular 
level. This is where functional metabolic imaging by SPECT, PET and modern MRI 
techniques come into play and excel. 
Histopathology, immunodiagnostic labeling assays to certain cellular antigens and other 
techniques like flow cytometry applied on excised tissue specimens are considered as the 
reference standard of diagnosis, of assessing aggressiveness and the likelihood of response 
to therapy, while also provide an estimate of prognosis. Yet tissue samples are obtained 
through surgical intervention, which is not always possible for numerous reasons already 
discussed. Furthermore, regional tissue heterogeneity within brain tumors may result in 
sampling errors. This underscores the importance of functional brain imaging in providing 
easily implemented, non-invasive diagnostic and prognostic alternative markers. 
Novel MRI techniques like MRS, DWI and DTI, together with certain PET and SPECT 
radiotracers, show promising results in the non-invasive assessment of tumor grade, 
proliferative potential, response to therapy and prognostication. In healthcare units without 
a PET facility, brain SPECT by 99mTc-TF can render useful metabolic information for newly 
diagnosed intracranial lesions prior to surgical intervention. Whether pertaining to gliomas 
or meningiomas, the lesions’ grade and proliferation can be efficaciously estimated and 
credible evaluations may be extracted for their prognosis. The method can also hold a role in 
the non-invasive diagnostic work-up of hemorrhagic intracerebral lesions, while it certainly 
has much to offer in differentiating radiation necrosis from brain tumor recurrence in 
patients previously treated by surgery and adjuvant radio-chemotherapy. 
Overall, there is gathering evidence to substantiate the need for larger scale, well-designed, 
prospective comparative studies between functional MR techniques and PET/SPECT 
radiotracers like 99mTc-TF, aiming to increase diagnostic accuracy and establish their clinical 
role in optimizing treatment decisions and reliably contribute on assessing patient 
prognosis. 
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